Durable insulin elimination after duodenal re-cellularization via electroporation therapy combined with glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes
These results suggest that duodenal ReCET combined with semaglutide is durable, allowing insulin elimination up to 24 months, and appears safe. Glycemic control was maintained, and metabolic health improved during the 24-month follow-up period.
Authors
- Thomas A. Bouwmeester (ORCID: https://orcid.org/0000-0003-0305-1498)
- F. Holleman (ORCID: https://orcid.org/0000-0001-5858-5089)
- Jacques J.G.H.M. Bergman (ORCID: https://orcid.org/0000-0001-7548-6955)
- Annieke C.G. van Baar (ORCID: https://orcid.org/0000-0002-1351-0267)
- Celine B.E. Busch (ORCID: https://orcid.org/0009-0007-7837-8088)
- Kim van den Hoek
- Suzanne Meiring
- Max Nieuwdorp
Institutions
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- iGIE
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.igie.2025.03.012
- Citations
- 1
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 2.01